Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1069094.RAW4jIxsTSXzZOiBUs8dPb68SU0UUMombdX2pOFAWugL4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1069094.RAW4jIxsTSXzZOiBUs8dPb68SU0UUMombdX2pOFAWugL4130_assertion type Assertion NP1069094.RAW4jIxsTSXzZOiBUs8dPb68SU0UUMombdX2pOFAWugL4130_head.
- NP1069094.RAW4jIxsTSXzZOiBUs8dPb68SU0UUMombdX2pOFAWugL4130_assertion description "[Although crizotinib manifests marked antitumor activity in individuals with non-small-cell lung cancer positive for ALK abnormalities, all treated patients ultimately develop resistance to this drug.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1069094.RAW4jIxsTSXzZOiBUs8dPb68SU0UUMombdX2pOFAWugL4130_provenance.
- NP1069094.RAW4jIxsTSXzZOiBUs8dPb68SU0UUMombdX2pOFAWugL4130_assertion evidence source_evidence_literature NP1069094.RAW4jIxsTSXzZOiBUs8dPb68SU0UUMombdX2pOFAWugL4130_provenance.
- NP1069094.RAW4jIxsTSXzZOiBUs8dPb68SU0UUMombdX2pOFAWugL4130_assertion SIO_000772 23584297 NP1069094.RAW4jIxsTSXzZOiBUs8dPb68SU0UUMombdX2pOFAWugL4130_provenance.
- NP1069094.RAW4jIxsTSXzZOiBUs8dPb68SU0UUMombdX2pOFAWugL4130_assertion wasDerivedFrom befree-2016 NP1069094.RAW4jIxsTSXzZOiBUs8dPb68SU0UUMombdX2pOFAWugL4130_provenance.
- NP1069094.RAW4jIxsTSXzZOiBUs8dPb68SU0UUMombdX2pOFAWugL4130_assertion wasGeneratedBy ECO_0000203 NP1069094.RAW4jIxsTSXzZOiBUs8dPb68SU0UUMombdX2pOFAWugL4130_provenance.